OncoLink Cancer Treatment and Resources

Role of PI3K/Akt Signaling in TRAIL and Radiation-induced Gastrointestinal (GI) Apoptosis



Reviewer: Charles Wood, MD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 18, 2006

Presenter: J. Plastaras
Presenter's Affiliation: University of Pennsylvania
Type of Session: Scientific

Background

  • Activation of the PI3K/Akt pathway leads to tumorigenesis, progression, and resistance to therapy; inhibition of the PI3K/Akt pathway has been shown to radiosensitize tumor cells in vitro and in animal models
  • The results of activation or inhibition of this pathway on normal tissue response to radiation (RT) are not well characterized
  • This study was designed to determine the effects of physiologic and genetic manipulation of Akt signaling on RT-induced GI apoptosis in mice

Materials and Methods

  • Activation or inhibition of the PI3K/Akt pathway was studied in both cell lines and in mice
  • Insulin, a potent stimulator of PI3K/Akt, was used to activate the pathway in vitro and in vivo
  • Akt1 knockout mice were utilized to study inactivation of the pathway in vivo
  • the role of the PI3K/Akt pathway in affecting pure apoptotic death in cell lines was determined by adding insulin and glucose (for pathway activation) to TRAIL (TNF-alpha Related Apoptosis Inducing Ligand); activation of the pathway was measured via Western blotting for phospho-Akt (P-Akt)
  • Mice were injected intraperitoneally with insulin and glucose, and stimulation of the PI3K/Akt pathway in vivo was measured via P-Akt (S473) immunofluorescence
  • To determine the effects of PI3k/Akt pathway activation on RT-induced apoptosis, mice were given a single fraction of 5 Gy 30 minutes after receiving intraperitoneal insulin and glucose
  • To determine the effects of Akt depletion on RT-induced apoptosis, Akt1 null and wild-type mice were given a single fraction of 5 Gy
  • GI tissues were harvested 6 hours, 1 day, and 4 days following RT, and apoptosis was measured via TUNEL immunofluorescence

Results

  • Insulin resulted in transiently increased levels of P-Akt levels, with a decrease after several hours in both cell lines and in the mouse colon; P-Akt levels were maximally elevated 30-90 minutes after injection
  • Treatment with insulin and glucose appeared to protect cell lines from TRAIL-induced apoptosis
  • RT caused apoptosis in the mouse ileum and colon at 6 hours, but induced minimal apoptosis in the liver or esophagus
  • Pre-treatment with insulin and glucose did not appear to protect against RT-induced apoptosis in the mouse ileum or colon
  • RT led to increased P-Akt levels 6 hours after treatment
  • RT caused increased apoptosis in the small intestinal crypt cells and colon cells of Akt1 null versus wild-type mice

Author's Conclusions

  • Activation of the PI3K/Akt pathway may contribute to therapeutic resistance
  • Stimulation of Akt with insulin can protect cells from TRAIL-induced apoptosis
  • Although additional stimulation of Akt by insulin did not protect against RT-induced apoptosis, RT alone caused increased levels of Akt, possibly secondary to an inherent adaptive response
  • Knockout of Akt-1 sensitized cells to RT-induced apoptosis in the gut
  • Although inhibition of the P13K/Akt pathway may increase sensitivity to both TRAIL- and RT-induced apoptosis, it may also result in increased GI toxicity

Clinical/Scientific Implications

This pre-clinical study was able to demonstrate modulation of radiation effects on normal tissues via manipulation of the PI3K/Akt signaling pathway in animal models. Additionally, resistance to TRAIL-induced apoptosis in vitro was increased by activation of the pathway. Though PI3K/Akt modulation may prove to be a promising mechanism for altering cell response to TRAIL or RT, response of normal tissues may also be altered, potentially decreasing any gains in the therapeutic ratio. These data also raise the interesting issue of the role of deranged Akt signaling, such as in diabetes and RT toxicity.

OncoLink I wish u knew...

Dr. Lin discusses head and neck cancer treatment, the potential side effects and the importance of being prepared and treated for them. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS